Potentially Powerful New Tool in Fight Against Pancreatic Cancer; Researchers from Osaka University Develop a Radioactive Monoclonal Antibody That May Enable the Diagnosis and Treatment of PDAC

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide, with a 5-year survival rate of less than 10%. Many PDAC tumors in early stage go undetected because they are not found using conventional imaging methods, including fluorodeoxyglucose positron emission tomography (PET) scans. To more efficiently combat this pancreatic cancer, a team led by researchers at Japan’s Osaka University is combining diagnostic and therapeutic procedures into a single integrated process: “theranostics.” In an article published on October 12, 2023 in the Journal of Nuclear Medicine, the team has developed a “radio-theranostics” strategy that uses a new radioactive antibody to target glypican-1 (GPC1), a protein highly expressed in PDAC tumors. Theranostics, particularly radio-theranostics, has been receiving increasing attention because, by radio-labeling the compounds used to target certain molecules in cancer cells, diagnosis and treatment can be carried out sequentially. The open-access article is titled “Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with 89Zr or 211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma.”

Login Or Register To Read Full Story